Adicet Bio (ACET) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Adicet Bio (ACET) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 77.8% versus a loss of 86.6%. Over five years, ACET leads with a -98.6% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($20.1 million vs $20.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | RNAZ |
|---|---|---|
| Share price | $2.14 | $1.16 |
| Market cap | $20.03M | $20.07M |
| 1-day change | -13.01% | -10.77% |
| YTD return | -74.58% | -83.02% |
| 1-year return | -77.78% | -86.57% |
| 5-year return | -98.58% | -100.00% |
| EPS (TTM) | $-7.53 | $-47.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-116.80M | $-34.66M |
| 52-week high | $11.15 | $12.60 |
| 52-week low | $2.12 | $1.01 |
| Distance from 52-week high | -80.81% | -90.79% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1527.57% | — |
| Average volume | 271.05K | 52.03K |
| Shares outstanding | 9.36M | 17.30M |
| Employees | 102 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
ACET vs RNAZ FAQ
Which is bigger, Adicet Bio or TransCode Therapeutics?
TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $20.07M compared with $20.03M for Adicet Bio (ACET).
Which stock has performed better over the past year, ACET or RNAZ?
ACET returned -77.78% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.